Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis

Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 Ong, 2008, Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease, J Hepatol, 49, 608, 10.1016/j.jhep.2008.06.018 Thun, 1997, Alcohol consumption and mortality among middle-aged and elderly U.S. adults, N Engl J Med, 337, 1705, 10.1056/NEJM199712113372401 Saad L. Majority in U.S. drink alcohol, averaging four drinks a week: beer edges out wine by 39% to 35% as drinkers' beverage of choice. Available at http://news.gallup.com/poll/156770/majority-drink-alcohol-averaging-four-drinks-week.aspx. Accessed: June 1, 2017. Tian, 2010, Variant in PNPLA3 is associated with alcoholic liver disease, Nat Genet, 42, 21, 10.1038/ng.488 Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, 1461, 10.1038/ng.257 Zhu, 2016, Gut microbiota produce alcohol and contribute to NAFLD, Gut, 65, 1232, 10.1136/gutjnl-2016-311571 Davies, 2002, Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in postmenopausal women: a randomized controlled trial, JAMA, 287, 2559, 10.1001/jama.287.19.2559 Sookoian, 2014, Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals, Gut, 63, 530, 10.1136/gutjnl-2013-305718 Moriya, 2015, Roles of alcohol consumption in fatty liver: a longitudinal study, J Hepatol, 62, 921, 10.1016/j.jhep.2014.11.025 Dunn, 2012, Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD), J Hepatol, 57, 384, 10.1016/j.jhep.2012.03.024 Cotrim, 2009, Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients, Eur J Gastroenterol Hepatol, 21, 969, 10.1097/MEG.0b013e328328f3ec Neuschwander-Tetri, 2010, Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease, Hepatology, 52, 913, 10.1002/hep.23784 Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929 Chalasani, 2009, Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design, Contemp Clin Trials, 30, 88, 10.1016/j.cct.2008.09.003 Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Kwon, 2014, Effect of lifetime alcohol consumption on the histological severity of non-alcoholic fatty liver disease, Liver Int, 34, 129, 10.1111/liv.12230 Dixon, 2001, Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese, Gastroenterology, 121, 91, 10.1053/gast.2001.25540 Mukamal, 2006, Alcohol consumption, physical activity, and chronic disease risk factors: a population-based cross-sectional survey, BMC Public Health, 6, 118, 10.1186/1471-2458-6-118 Sookoian, 2017, Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease, Alimentary Pharmacology & Therapeutics, 44, 1224, 10.1111/apt.13828 Hoofnagle, 2013, Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis, Aliment Pharmacol Ther, 38, 134, 10.1111/apt.12352 Nanau, 2015, Biomolecules and biomarkers used in diagnosis of alcohol drinking and in monitoring therapeutic interventions, Biomolecules, 5, 1339, 10.3390/biom5031339 Stockwell, 2004, Under-reporting of alcohol consumption in household surveys: a comparison of quantity–frequency, graduated–frequency and recent recall, Addiction, 99, 1024, 10.1111/j.1360-0443.2004.00815.x Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368 Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016/j.cgh.2014.04.014 Unalp-Arida, 2016, Noninvasive fatty liver markers predict liver disease mortality in the U.S. population, Hepatology, 63, 1170, 10.1002/hep.28390 VanWagner, 2017, Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease, Gastroenterology, 153, 1260, 10.1053/j.gastro.2017.08.012 Rotman, 2010, The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease, Hepatology, 52, 894, 10.1002/hep.23759